"Fluorouracil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
| Descriptor ID |
D005472
|
| MeSH Number(s) |
D03.383.742.698.875.404
|
| Concept/Terms |
Fluorouracil- Fluorouracil
- 5FU
- 5-FU
- 5-Fluorouracil
- 5 Fluorouracil
- Fluoruracil
Efudix- Efudix
- Fluoro-Uracile ICN
- Fluoro Uracile ICN
- Efudex
|
Below are MeSH descriptors whose meaning is more general than "Fluorouracil".
Below are MeSH descriptors whose meaning is more specific than "Fluorouracil".
This graph shows the total number of publications written about "Fluorouracil" by people in this website by year, and whether "Fluorouracil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 7 | 17 | 24 |
| 1996 | 4 | 8 | 12 |
| 1997 | 3 | 17 | 20 |
| 1998 | 5 | 25 | 30 |
| 1999 | 9 | 22 | 31 |
| 2000 | 4 | 21 | 25 |
| 2001 | 4 | 24 | 28 |
| 2002 | 5 | 17 | 22 |
| 2003 | 11 | 29 | 40 |
| 2004 | 12 | 31 | 43 |
| 2005 | 6 | 38 | 44 |
| 2006 | 5 | 44 | 49 |
| 2007 | 9 | 32 | 41 |
| 2008 | 4 | 23 | 27 |
| 2009 | 6 | 34 | 40 |
| 2010 | 6 | 26 | 32 |
| 2011 | 2 | 24 | 26 |
| 2012 | 1 | 21 | 22 |
| 2013 | 7 | 16 | 23 |
| 2014 | 4 | 25 | 29 |
| 2015 | 2 | 17 | 19 |
| 2016 | 4 | 14 | 18 |
| 2017 | 3 | 20 | 23 |
| 2018 | 1 | 9 | 10 |
| 2019 | 3 | 12 | 15 |
| 2020 | 4 | 19 | 23 |
| 2021 | 2 | 10 | 12 |
| 2022 | 0 | 11 | 11 |
| 2023 | 0 | 9 | 9 |
| 2024 | 6 | 9 | 15 |
To return to the timeline,
click here.
Below are the most recent publications written about "Fluorouracil" by people in Profiles.
-
The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress. Cancer Biol Ther. 2024 Dec 31; 25(1):2421584.
-
Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Clin Cancer Res. 2024 Nov 01; 30(21):4932-4942.
-
Targeted Dynamic Phospho-Proteogenomic Analysis of Gastric Cancer Cells Suggests Host Immunity Provides Survival Benefit. Mol Cell Proteomics. 2024 Dec; 23(12):100870.
-
From mitochondria to tumor suppression: ACAT1's crucial role in gastric cancer. Front Immunol. 2024; 15:1449525.
-
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024 Aug; 9(8):103663.
-
Transarterial (chemo)embolisation versus systemic chemotherapy for colorectal cancer liver metastases. Cochrane Database Syst Rev. 2024 08 09; 8:CD012757.
-
Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study. Cancer Biol Med. 2024 Jul 26; 21(9).
-
Postoperative Adverse Events Following Neoadjuvant Therapy and Surgery for Borderline Resectable Pancreatic Cancer in a Phase 2 Clinical Trial (Alliance A021501). Ann Surg Oncol. 2024 Oct; 31(10):7033-7042.
-
Pembrolizumab Plus Binimetinib With or Without Chemotherapy for MSS/pMMR Metastatic Colorectal Cancer: Outcomes From KEYNOTE-651 Cohorts A, C, and E. Clin Colorectal Cancer. 2024 Jun; 23(2):183-193.
-
Pembrolizumab Plus mFOLFOX7 or FOLFIRI for Microsatellite Stable/Mismatch Repair-Proficient Metastatic Colorectal Cancer: KEYNOTE-651 Cohorts B and D. Clin Colorectal Cancer. 2024 Jun; 23(2):118-127.e6.